Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 59.3141
- Book/Share 20.4356
- PB 37.4926
- Debt/Equity 2.1838
- CurrentRatio 1.2777
- ROIC 0.277
- MktCap 686209105638.0
- FreeCF/Share -0.0559
- PFCF -13669.5041
- PE 49.6451
- Debt/Assets 0.3954
- DivYield 0.0076
- ROE 0.8836
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Read More
Cramer Loves These Dividend Stocks
Published: September 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points Jim Cramer's Mad Money offers insights valuable to income investors, despite his broader focus on growth.
Read More
Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption
Published: August 28, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron's convenience, scalability, and potential dual-indication label position it as a key driver for Eli Lilly's revenue diversification and premium valuation. Despite payer coverage and tolerability challenges, the massive eligible population and orforglipron's advantages should drive exponential sales growth.
Read More
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
Read More
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.
Read More
Eli Lilly's Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race
Published: August 27, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Eli Lilly's (LLY) Zepbound has outshone Novo Nordisk's Wegovy, achieving superior weight-loss results in clinical trials.
Read More
The bear case on Eli Lilly has played out, says only firm to have called it a sell
Published: August 27, 2025 by: Market Watch
Sentiment: Neutral
The bear case for Eli Lilly has now played out following the reaction to the drugmaker's oral obesity drug trial, an analyst said Wednesday in upgrading the stock.
Read More
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit Results reinforce two years of Verzenio plus endocrine therapy as the standard of care in HR+, HER2-, node-positive, early breast cancer at a high risk of recurrence INDIANAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the primary overall survival (OS) analysis of the Phase 3 …
Read More
Durable Goods Orders Decreased Less Than Expected
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Pre-market activity is somewhat better than earlier in the trading session this morning, following a less-bad Durable Goods report for July. We also appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.
Read More
Top Stock Movers Now: Eli Lilly, EchoStar, Constellation Brands, and More
Published: August 26, 2025 by: Investopedia
Sentiment: Neutral
U.S. equities were little changed at midday on limited market-driving corporate earnings news and economic data. The Dow Jones Industrial Average, S&P 500, and Nasdaq all moved by small amounts.
Read More
Eli Lilly advances weight loss pill towards regulatory submissions after successful trial
Published: August 26, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) shares moved higher Tuesday after the company reported positive late-stage trial results for its experimental oral obesity and diabetes drug, orforglipron. The Phase 3 study, known as ATTAIN-2, tested orforglipron in adults with obesity or overweight who also have Type 2 diabetes.
Read More
Eli Lilly Stock Climbs on Weight-Loss Drug Trial Results
Published: August 26, 2025 by: Schaeffers Research
Sentiment: Positive
Shares of pharmaceutical giant Eli Lilly and Co (NYSE:LLY) are on the rise today, up 3.7% at $720.07 at last check.
Read More
Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval
Published: August 26, 2025 by: Investopedia
Sentiment: Positive
Eli Lilly (LLY) shares gained more than 4% soon after the opening bell Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.
Read More
Lilly obesity-pill trial results find a warmer reception on Wall Street this time around
Published: August 26, 2025 by: Market Watch
Sentiment: Positive
Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.
Read More
Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Published: August 25, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D.
Read More
The Big 3: LLY, BA, CVS
Published: August 22, 2025 by: Schwab Network
Sentiment: Positive
Dan Deming considers Friday's trading action after Jerome Powell's Jackson Hole speech "remarkable." On stocks he's watching ahead, he expects Eli Lilly (LLY) to rebound off a significant sell-off, Boeing (BA) to soar on its financial recovery and aircraft backlog, and CVS Health (CVS) to capture more market share in the pharma space.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Read More
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
Published: August 22, 2025 by: The Motley Fool
Sentiment: Neutral
Eli Lilly (LLY 0.73%) has been a terrific stock to own over the past 15 years; it has consistently outperformed the broader equities market. However, the drugmaker may not be able to pull that off in 2025, because several setbacks this year have sunk its stock price.
Read More
Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Aug. 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive vice president and president of Lilly International, will take part in a fireside chat at 9:30 a.m.
Read More
Eli Lilly and Company Investors: Company Investigated by the Portnoy Law Firm
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets
Published: August 21, 2025 by: MarketBeat
Sentiment: Positive
Most investors have noticed that most stocks in the healthcare sector have declined to levels not seen in a while, making this an area of interest for those looking into the next potential upswing in their portfolios. However, for those who are okay with individual stock picking and taking on a bit more risk, there is one narrative to follow in the coming months.
Read More
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
Published: August 20, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date.
Read More
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
Published: August 19, 2025 by: Benzinga
Sentiment: Negative
Investors appear disappointed with Viking Therapeutics Inc.'s VKTX data from its Phase 2 trial of an obesity pill.
Read More
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
Published: August 19, 2025 by: Benzinga
Sentiment: Negative
On Tuesday, Viking Therapeutics Inc. VKTX released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Read More
Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's FDA approval for Wegovy in MASH and aggressive Ozempic pricing boost its position, despite recent stock declines and competitive pressure from Eli Lilly and Company. Both NVO and LLY face regulatory headwinds from U.S. drug pricing demands, but I believe much of the bad news is already priced in for both. Novo's strategic pricing, strong clinical data, and attractive valuation make it my preferred long-term pick, though both stocks offer upside from current levels.
Read More
2 Phenomenal Dividend Growth Stocks That Insiders Are Buying Hand Over Fist
Published: August 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Dividend growth investing offers stable income and capital appreciation through compounding returns.
Read More
Lilly Stock Down 5% This Month: Should You Buy the Dip?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
Read More
Eli Lilly: A Textbook Insider Buying Play
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
I initiate my coverage on Eli Lilly with a 'Buy' after an eventful Q2 earnings season. The stock looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and Mounjaro sales. LLY management is confident that the momentum in the weight loss segment will hold up. FY 2025 guidance was revised upwards for both the top and bottom lines.
Read More
Eli Lilly said it is in talks to raise drug prices in Europe, starting with weight-loss drug Mounjaro in the U.K., so it can meet President Trump's goal of bringing down prices in the U.S.
Published: August 14, 2025 by: WSJ
Sentiment: Negative
The move is part of the company's plan to renegotiate drug prices across other developed nations
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000